Pazopanib for the treatment of soft-tissue sarcoma

Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranch&egrave;re-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Patholog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Heudel P, Cassier P, Derbel O, Dufresne A, Meeus P, Thiesse P, Ranch&egrave;re-Vince D, Blay JY, Ray-Coquard I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/b1967181c70045e88f03c8d5e700d598
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1967181c70045e88f03c8d5e700d598
record_format	dspace
spelling	oai:doaj.org-article:b1967181c70045e88f03c8d5e700d5982021-12-02T00:44:32ZPazopanib for the treatment of soft-tissue sarcoma1179-1438https://doaj.org/article/b1967181c70045e88f03c8d5e700d5982012-10-01T00:00:00Zhttp://www.dovepress.com/pazopanib-for-the-treatment-of-soft-tissue-sarcoma-a11370https://doaj.org/toc/1179-1438Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranch&egrave;re-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Pathology, Leon Berard Center, Lyon, 5EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, FranceAbstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitorHeudel PCassier PDerbel ODufresne AMeeus PThiesse PRanch&egrave;re-Vince DBlay JYRay-Coquard IDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2012, Iss default, Pp 65-70 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Heudel P Cassier P Derbel O Dufresne A Meeus P Thiesse P Ranch&egrave;re-Vince D Blay JY Ray-Coquard I Pazopanib for the treatment of soft-tissue sarcoma
description	Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranch&egrave;re-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Pathology, Leon Berard Center, Lyon, 5EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, FranceAbstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitor
format	article
author	Heudel P Cassier P Derbel O Dufresne A Meeus P Thiesse P Ranch&egrave;re-Vince D Blay JY Ray-Coquard I
author_facet	Heudel P Cassier P Derbel O Dufresne A Meeus P Thiesse P Ranch&egrave;re-Vince D Blay JY Ray-Coquard I
author_sort	Heudel P
title	Pazopanib for the treatment of soft-tissue sarcoma
title_short	Pazopanib for the treatment of soft-tissue sarcoma
title_full	Pazopanib for the treatment of soft-tissue sarcoma
title_fullStr	Pazopanib for the treatment of soft-tissue sarcoma
title_full_unstemmed	Pazopanib for the treatment of soft-tissue sarcoma
title_sort	pazopanib for the treatment of soft-tissue sarcoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/b1967181c70045e88f03c8d5e700d598
work_keys_str_mv	AT heudelp pazopanibforthetreatmentofsofttissuesarcoma AT cassierp pazopanibforthetreatmentofsofttissuesarcoma AT derbelo pazopanibforthetreatmentofsofttissuesarcoma AT dufresnea pazopanibforthetreatmentofsofttissuesarcoma AT meeusp pazopanibforthetreatmentofsofttissuesarcoma AT thiessep pazopanibforthetreatmentofsofttissuesarcoma AT ranchampegraverevinced pazopanibforthetreatmentofsofttissuesarcoma AT blayjy pazopanibforthetreatmentofsofttissuesarcoma AT raycoquardi pazopanibforthetreatmentofsofttissuesarcoma
_version_	1718403519298404352

Pazopanib for the treatment of soft-tissue sarcoma

Ejemplares similares